Prothena Corporation plc
$10.79
▼
-1.69%
2026-04-21 08:57:01
www.prothena.com
NMS: PRTA
Explore Prothena Corporation plc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$583.55 M
Current Price
$10.79
52W High / Low
$11.69 / $4.32
Stock P/E
—
Book Value
$5.21
Dividend Yield
—
ROCE
-64.54%
ROE
-63.62%
Face Value
—
EPS
$-4.53
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
67
Beta
-0.33
Debt / Equity
2.98
Current Ratio
7.72
Quick Ratio
7.72
Forward P/E
-10.1
Price / Sales
58.37
Enterprise Value
$266.09 M
EV / EBITDA
-1.45
EV / Revenue
27.48
Rating
None
Target Price
$21
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Novavax, Inc. | $8.67 | 3.2 | $1.41 B | — | 76.84% | -117.16% | $11.97 / $5.8 | $-0.79 |
| 2. | EyePoint, Inc. | $15.07 | — | $1.26 B | — | -74.45% | -72.19% | $19.11 / $5.3 | $3.7 |
| 3. | Voyager Therapeutics, Inc. | $4.23 | — | $252.11 M | — | -58.41% | -48.29% | $5.55 / $2.65 | $3.32 |
| 4. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 5. | Caris Life Sciences, Inc. | $21.24 | — | $5.98 B | — | 4.52% | -45.37% | $42.5 / $16.28 | $2.04 |
| 6. | Veradermics, Incorporated | $73.97 | — | $2.85 B | — | -49.88% | -72.06% | $80.9 / $32 | $-131.48 |
| 7. | REGENXBIO Inc. | $9.47 | — | $488.82 M | — | -48.13% | -1.07% | $16.19 / $5.85 | $2.02 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.02 M | 2.42 M | 4.42 M | 2.83 M | 2.12 M | — |
| Operating Profit | -27.21 M | -39.76 M | -52.01 M | -65.58 M | -64.9 M | — |
| Net Profit | -21.59 M | -36.54 M | -125.77 M | -60.2 M | -57.96 M | — |
| EPS in Rs | -0.4 | -0.68 | -2.34 | -1.12 | -1.08 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 9.68 M | 135.16 M | 91.37 M | 53.91 M |
| Operating Profit | -184.56 M | -154.56 M | -191.04 M | -131.56 M |
| Net Profit | -244.09 M | -122.31 M | -147.03 M | -116.95 M |
| EPS in Rs | -4.53 | -2.27 | -2.73 | -2.17 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 326.8 M | 547.11 M | 696.38 M | 758.03 M |
| Total Liabilities | 46.33 M | 60.18 M | 135.02 M | 135.99 M |
| Equity | 280.47 M | 486.93 M | 561.37 M | 622.04 M |
| Current Assets | 315.19 M | 485.41 M | 639.28 M | 719.1 M |
| Current Liabilities | 40.84 M | 48.5 M | 56.89 M | 50.15 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -163.58 M | -150.05 M | -133.91 M | -108.82 M |
| Investing CF | -0.14 M | -0.3 M | -2.77 M | -0.46 M |
| Financing CF | -0.14 M | 1.55 M | 45.1 M | 241.46 M |
| Free CF | -163.72 M | -150.35 M | -136.72 M | -109.28 M |
| Capex | -0.14 M | -0.3 M | -2.81 M | -0.46 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 47.92% | 69.5% | — | — |
| Earnings Growth % | 16.81% | -25.72% | — | — |
| Profit Margin % | -90.49% | -160.91% | -216.95% | — |
| Operating Margin % | -114.36% | -209.08% | -244.05% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -113.7% | -208.06% | -242.67% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.